When pulmonary hypertension develops in systemic lupus erythematosus (SLE) the usual cause is chronic thromboembolism or interstitial lung disease 1±4 . Very occasionally, however, it has the features of the primary form of pulmonary hypertension 1 .
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CASE HISTORY
A Caucasian woman aged 42 was admitted with a twomonth history of severe fatigue and progressive exertional dyspnoea (New York Heart Association class III). She also reported polyarthralgia, Raynaud's phenomenon and lowgrade fever for the past year. On admission, temperature was 38.5 8C, blood pressure 110/68 mmHg and pulse 100 per minute; she was mildly tachypnoeic. Lung ®elds were clear but there were signs of right ventricular failureÐ raised jugular pressure and lower-limb oedema. Haemoglobin was 9.0 g/dL, leucocytes 4.1610 9 /L with absolute lymphopenia (0.3610 9 /L), platelet count normal, erythrocyte sedimentation rate 133 mm/h, C-reactive protein 2.5 mg/dL, C3 and C4 complement depressed, and gamma-globulin high at 29 g/L. Liver and renal function tests were normal and HIV-1 and HIV-2 serology was negative. Antinuclear antibodies (titre41/256) and double-stranded anti-DNA 1130 U/L were detected; direct Coombs test was positive with IgG and C3 speci®cities; she had proteinuria of 760 mg/day. Systemic lupus erythematosus was diagnosed but the right heart failure demanded further investigation. Chest X-ray showed clear lung ®elds, and enlargement of both pulmonary arteries was seen clearly on magnetic resonance imaging ( Figure 1) ; transoesophageal doppler echocardiography disclosed a high pulmonary artery systolic pressure (PASP) of 45 mmHg at rest with peak values of 78 mmHg on exertion; myocardial, pericardial and valvular heart disease were excluded. On pulmonary function testing, CO diffusing capacity (D L CO) was very low at 42%; and restrictive lung diseases were ruled out, as was thromboembolism, by repeated arterial blood gases and normal ventilation±perfusion lung scanning. Antiphospholipid antibodies were persistently negative and computed tomography did not show interstitial lung disease. On cardiac catheterization the severe pulmonary hypertension was con®rmed (PASP 42 mmHg); pulmonary vascular resistance was high at 352 dyne.s.cm 75 and capillary wedge pressure was normal (15 mmHg). Methylprednisone 500 mg twice daily was prescribed for three days, followed by prednisone 1 mg/kg and azathioprine 2.5 mg/kg per day, maintained for two years. In the next few months the patient's functional status improved with progressive lessening of exertional dyspnoea and reduction of PASP on repeated doppler echocardiography. By the twelfth month of follow-up PSAP was 30 mmHg and D L CO was 82%. Three years after diagnosis and one year after stopping azathioprine and prednisone, the patient is symptom-free.
COMMENT
In a series of 24 patients with pulmonary hypertension and SLE, Asherson et al. 1 identi®ed antiphospholipid antibodies in 16. These antibodies are associated with microthrombosis in the alveolar capillaries 3, 4 . But in addition to the thrombotic mechanism 3,4 it has been proposed that antiendothelial antibodies can lead to release of interleukin-6 by endothelial cells in alveolar capillaries, so increasing in another way pulmonary vascular resistance 5 .The usual view is that this pulmonary hypertension resembling the`primary' form of the disease will be resistant to treatment 6 ; however, we are not the ®rst to contest this view. Before us, Goupille 7 and Groen 8 and their coworkers reported reductions in pulmonary hypertension when treating two patients with corticosteroids and cyclophosphamide. Our patient differs from theirs in having gone into a complete remission which was sustained a year after stopping azathioprine and prednisone. We conclude that, in a patient with this rare and usually fatal manifestation of SLE, aggressive immunosuppressive therapy is warranted. When sarcomatoid renal cell carcinoma is found in ventricular myocardium, it has usually extended along the inferior vena cava.
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CASE HISTORY
A woman aged 50 with right loin pain, microscopic haematuria, weight loss and raised erythrocyte sedimentation rate (ESR) was found to have a localized right renal mass without vena caval involvement on ultrasound or computed tomographic imaging. A radical nephrectomy was performed and the specimen, weighing 350 g and measuring 156865 cm, had a large pale ®rm mass in the upper two-thirds. Microscopically, the tumour diffusely invaded the stroma and renal tubules but did not breach the capsule. It consisted predominantly of large spindle cells, mixed in some areas with large squamoid cells. Morular (whorl-like) aggregates were seen with the squamoid cells (Figure 1) . Although some areas contained cells with translucent cytoplasm, typical clear-cell carcinoma was not seen. No cartilaginous or osteoid differentiation was identi®ed. Frequent mitoses, extensive patchy necrosis and microvascular invasion were observed. There was no evidence of localized tumour developing in the collecting ducts, and the pelvic urothelium was normal. No tumour was found in the renal vein at the hilum. On immunostaining the tumour cells were strongly positive for vimentin and cytokeratin (AE1/AE3) but negative for epithelial membrane antigen ( 
